Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P305: No increased risk for infections with thiopurine-induced leukopenia in inflammatory bowel disease patients without a variant in thiopurine S-methyltransferaseECCO '16 Amsterdam
Year: 2016
Authors:

M. Broekman*1, M. Coenen2, C. van Marrewijk2, G. Wanten1, L. Derijks3, S. Vermeulen2, 4, D. Wong5, O. Klungel6, A. Verbeek4, P. Hooymans5, H. Scheffer2, H.-J. Guchelaar7, D. de Jong1

1Radboud University Medical Centre, Department of Gastroenterology, Nijmegen, Netherlands, 2Radboud University Medical Centre, Department of Human Genetics, Nijmegen, Netherlands, 3Maxima Medical Centre Loc. Veldhoven, Department of Gastroenterology and Hepatology, Veldhoven, Netherlands, 4Radboud University Medical Centre, Radboud Institute for Health Sciences, Nijmegen, Netherlands, 5Zuyderland Medical Centre, Department of Clinical Pharmacy, Pharmacology and Toxicology, Sittard, Netherlands, 6Utrecht University, Departement of Pharmacoepidemiology and Clinical Pharmacotherapy, Utrecht, Netherlands, 7Leiden University Medical Centre, Department of Clinical Pharmacy and Toxicology, Leiden, Netherlands

P306: The real-life experience of vedolizumab efficacy and safety in ulcerative colitis: a prospective observational multicentre cohort studyECCO '16 Amsterdam
Year: 2016
Authors:

A. Amiot*1, L. Peyrin-Biroulet2, C. Stefanescu3, J. C. Grimaud4, J. Filippi5, B. Pariente6, X. Roblin7, R. Altwegg8, D. Laharie9, P. Marteau10, A. Buisson11, C. Trang-Poisson12, S. Nancey13, G. Savoye14, S. Viennot15, H. Brixi-Benmansour16, F. Carbonnel17, Y. Bouhnik3

1Henri Mondor Hospital, Gastroenterology, Creteil, France, 2CHU Nancy, Department of Gastroenterology and Hepatology, Vandoeuvre-Lès-Nancy, France, 3APHP Beaujon, Department of Gastroenterology, Clichy, France, 4Hospital Nord, Department of Gastroenterology and Hepatology, Marseille, France, 5Archet 2 Hospital, Department of Gastroenterology, Nice, France, 6CHRU Lille, Department of Gastroenterology, Lille, France, 7University of Saint Etienne, Department of Gastroenterology, Saint Etienne, France, 8CHU Montpellier Saint Eloi Hospital, Department of Gastroenterology, Montpellier, France, 9CHU Bordeaux, Department of Gastroenterology, Bordeaux, France, 10Hospital Lariboisière, Department of Gastroenterology, Paris, France, 11CHU Estaing, Department of Gastroenterology, Clermont-Ferrand, France, 12CHU Hotel Dieu, Department of Gastroenterology, Nantes, France, 13Hospital Edouard Herriot, Department of Gastroenterology and Hepatology, Lyon, France, 14CHU Rouen, Department of Gastroenterology, Rouen, France, 15Hospital Cote de Nacre, Department of Gastroenterology, Caen Cede, France, 16Robert Debre Hospital, Department of Gastroenterology, Reims, France, 17CHU Bicêtre, Department of Gastroenterology, Le Kremlin-Bicêtre, France

P307: Safety, efficacy, and pharmacokinetics of golimumab in patients with moderately to severely Active ulcerative colitis: PURSUIT-SC long-term extensionECCO '16 Amsterdam
Year: 2016
Authors:

W. Reinisch*1, P. Gibson2, W. J. Sandborn3, B. Feagan4, C. Marano5, R. Strauss5, J. Johanns5, H. Zhang5, L. Padgett5, O. J. Adedokun5, J.-F. Colombel6, J. Collins7, P. Rutgeerts8, D. Tarabar9

1Universitätsklinik für Innere Medizin III and McMaster University, Vienna and Hamilton, Austria, 2Alfred Hospital, Melbourne, Australia, 3University of California San Diego, Division of Gastroenterology, La Jolla, California, United States, 4Robarts Clinical Trials Inc., Robarts Research Institute, University of Western Ontario, London, Ontario, Canada, 5Janssen R & D, LLC, Spring House, Pennsylvania, United States, 6Mount Sinai, Icahn School of Medicine, New York, New York, United States, 7Oregon Health Sciences University, Department of Gastroenterology, Portland, Oregon, United States, 8University Hospital Gasthuisberg, Department of Haematology, Leuven, Netherlands, 9Military Medical Academy, Department of Gastroenterology and Hepatology, Belgrade, Serbia

P308: Predictors of loss of response to adalimumab therapy: the importance of therapeutic drug monitoring in inflammatory bowel diseasesECCO '16 Amsterdam
Year: 2016
Authors:

Z. Kurti*1, Z. Vegh1, M. Rutka2, L. Gonczi1, K. Farkas2, K. Gecse1, P. A. Golovics1, B. Szalay3, T. Molnar2, P. Lakatos1

1Semmelweis University, First Department of Medicine, Budapest, Hungary, 2University of Szeged, First Department of Medicine, Szeged, Hungary, 3Semmelweis University, Department of Laboratory Medicine, Budapest, Hungary

P309: High infliximab trough levels are associated with better control of inflammation in inflammatory bowel diseaseECCO '16 Amsterdam
Year: 2016
Authors:

D. Drobne*1, T. Kurent1, P. Rajar2, M. Slak3, M. Kozelj1, G. Novak1, N. Smrekar1, S. Plut1, A. Smid1, J. Osredkar4, B. Stabuc1, I. Ferkolj1

1University Medical Centre Ljubljana, Department of Gastroenterology and Hepatology, Ljubljana, Slovenia, 2University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia, 3Faculty of Pharmacy, Ljubljana, Slovenia, 4University Medical Centre Ljubljana, Clinical Institute of clinical chemistry and biochemistry, Ljubljana, Slovenia

P310: Patient-reported quality of life during golimumab induction for moderate-to-severe ulcerative colitis in the United Kingdom: results from the GO-COLITIS studyECCO '16 Amsterdam
Year: 2016
Authors:

P. Irving*1, C. Probert2, D. R. Gaya3, P. J. Hamlin4, S. Sebastian5, G. Gillespie6, H. Tate6, C. Wheeler6

1Guy’s and St Thomas’ Hospitals, London, United Kingdom, 2University of Liverpool, Liverpool, United Kingdom, 3Glasgow Royal Infirmary, Glasgow, United Kingdom, 4Leeds Teaching Hospitals Trust, Leeds, United Kingdom, 5Hull & East Yorkshire NHS Trust, Hull, United Kingdom, 6MSD UK, Hoddesdon, United Kingdom

P311: No difference in immunogenicity of the original and biosimilar infliximab in patients with inflammatory bowel disease: short-term resultsECCO '16 Amsterdam
Year: 2016
Authors:

K. Malickova1, D. Duricova*2, M. Kolar2, M. Bortlik2, V. Hruba2, N. Machkova2, K. Mitrova2, M. Lukas Jr.2, M. Lukas2

1First Medical Faculty and General Teaching Hospital, Charles University, Institute of Medical Biochemistry and Laboratory Diagnostics, Prague, Czech Republic, 2ISCARE, IBD clinical and research centre, Prague, Czech Republic

P312: Has IBD specialists’ awareness of biosimilar monoclonal antibodies changed? Results from a survey amongst ECCO membersECCO '16 Amsterdam
Year: 2016
Authors:

S. Danese*1, 2, G. Fiorino1, P. Michetti3

1Humanitas Research Hospital, IBD Centre, Gastroenterology, Rozzano, Milan, Italy, 2Humanitas University, Biomedical Sciences, Rozzano, Milan, Italy, 3Clinique La Source-Beaulieu, Crohn and Colitis Centre, Lausanne, Switzerland

P313: Comparison of accelerated infliximab induction versus standard induction treatment in acute severe ulcerative colitisECCO '16 Amsterdam
Year: 2016
Authors:

M. Choy*1, 2, 3, D. Seah1, 3, A. Gorelik4, F. Macrae5, M. Sparrow6, W. R. Connell2, G. Moore7, D. Van Langenberg8, P. De Cruz1, 3

1Austin Health, Department of Gastroenterology, Melbourne, Australia, 2St Vincent’s Hospital, Department of Gastroenterology, Melbourne, Australia, 3University of Melbourne, Department of Medicine, Melbourne, Australia, 4Royal Melbourne Hospital, Melbourne EpiCentre, Melbourne, Australia, 5Royal Melbourne Hospital, Department of Gastroenterology, Melbourne, Australia, 6The Alfred Hospital, Department of Gastroenterology, Melbourne, Australia, 7Monash Health, Department of Gastroenterology, Melbourne, Australia, 8Eastern Health, Department of Gastroenterology, Melbourne, Australia

P314: Proposal for an anti-tumour necrosis factor–exit strategy based on trough serum levelECCO '16 Amsterdam
Year: 2016
Authors:

U. Helwig*1, F. Lutter1, N. Koppka2, S. Schreiber3

1University of Kiel, Medical Practice for Internal Medicine, Oldenburg, Germany, 2Medical Practice for Internal Medicine, Oldenburg, Germany, 3Department of Internal Medicine I - Gastroenterology, Hepatology, Nutrition and Geriatric Medicine, University Hospital Schleswig-Holstein, campus Kiel, Kiel, Germany

P315: Effect of age on beliefs about and adherence to medications in patients with inflammatory bowel disease: results from the ALIGN studyECCO '16 Amsterdam
Year: 2016
Authors:

P. Michetti*1, L. Peyrin-Biroulet2, M. S. Silverberg3, E. Louis4, J. Weinman5, J. Sommer6, J. Petersson7, B. Pappalardo7, P. Nurwakagari8

1IBD Centre La Source-Beaulieu, Lausanne, Switzerland, 2Inserm U954 and Department of Gastroenterology, Université de Lorraine, Vandoeuvre-les-Nancy, France, 3Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, University of Toronto, Toronto, Canada, 4CHU de Liège et Université de Liège, Liège, Belgium, 5Institute of Pharmaceutical Sciences & Institute of Psychiatry, King’s College, London, United Kingdom, 6GKM Gesellschaft für Therapieforschung mbH, Munich, Germany, 7AbbVie Inc., North Chicago, Illinois, United States, 8AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany

P316: Prognosis of patients with inflammatory bowel disease in clinical remission after de-escalation of infliximab maintenance therapy from 8 to 12 weeksECCO '16 Amsterdam
Year: 2016
Authors:

J. M. Vázquez-Morón, B. Benítez-Rodríguez*, H. Pallarés-Manrique, M. Ramos-Lora

Hospital General Juan Ramón Jiménez, Gastroenterology Unit, Huelva, Spain

P317: Health care costs associated with standard inflammatory bowel disease care in Australia and opportunities to improve care: a tertiary centre studyECCO '16 Amsterdam
Year: 2016
Authors:

B. Jackson*1, R. Ma1, A. Gorelik2, D. Con1, D. Liew2, P. De Cruz1

1Austin Health, Gastroenterology, Melbourne, Australia, 2Melbourne Health, Melbourne, Australia

P318: Does anti-tumour necrosis factor therapy decrease the risk of initial intestinal resection after the diagnosis of Crohn’s disease? A retrospective single-centre studyECCO '16 Amsterdam
Year: 2016
Authors:

Y. Nagata*1, M. Esaki1, A. Hirano1, J. Umeno1, Y. Maehata1, T. Torisu1, T. Moriyama1, T. Matsumoto2, T. Kitazono1

1Graduate School of Medical Sciences, Kyushu University, Department of Medicine and Clinical Science, Fukuoka, Japan, 2School of Medicine, Iwate Medical University, Division of Gastroenterology, Department of Internal Medicine, Morioka, Japan

P319: Combining anti-inflammatory treatment with antiviral treatment in severe cytomegalovirus-positive ulcerative colitis does not affect colectomy rate: a retrospective European multicentre studyECCO '16 Amsterdam
Year: 2016
Authors:

U. Kopylov*1, K. Papamichael2, 3, K. Katsanos4, M. Waterman5, A. Bar-Gil Shitrit6, T. Boysen7, F. Portela8, A. Peixoto9, A. Szilagyi10, M. Silva9, G. Maconi11, O. Har-Noy1, P. Bossuyt12, G. Mantzaris2, M. Barreiro de Acosta13, M. Chaparro14, D. Christodoulou4, R. Eliakim1, J.-F. Rahier15, F. Magro9, S. Ben-Horin16, X. Roblin17

1Sheba Medical Centre, Gastroenterology, Tel Hashomer, Israel, 2Evaggelismos Hospital, Gastroenterology, Athens, Greece, 3KU Leuven, Department of Clinical and Experimental Medicine, Translational Research Centre for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 4University of Ioannina, Gastroenterology, Ioannina, Greece, 5Rambam Healthcare Campus, Gastroenterology, Haifa, Israel, 6Shaare Zedek Medical Centre, Digestive diseases Institute, Jerusalem, Israel, 7Herlev University Hospital, Gastroenterology, Herlev, Denmark, 8Hospital Universidade Coimbra, Gastroenterology, Coimbra, Portugal, 9Centro Hospitalar São João, Gastroenterology, Porto, Portugal, 10Jewish General Hospital, Department of Gastroenterology, Montreal, Canada, 11Luigi Sacco’ University Hospital, Gastroenterology, Milan, Italy, 12Imelda GI clinical research Centre,, Gastroenterology, Bonheiden, Belgium, 13University Hospital of Santiago de Compostela, IBD Unit, Gastroenterology Department, Santiago de Compostela, Spain, 14Hospital Universitario de La Princesa, Gastroenterology, Madrid, Spain, 15CHU Dinant Godinne, UCL Namur, Gastroenterology, Yvoir, Belgium, 16Chaim Sheba Medical Centre, Gastroenterology, Ramat Gan, Israel, 17CHU de Saint-Etienne, Gastroenterology, Saint-Etiennne, France

P320: Clinical and economic effect of short infliximab infusion protocol in patients with inflammatory bowel diseases: a multicentre studyECCO '16 Amsterdam
Year: 2016
Authors:

M. Cappello*1, G. Costantino2, A.C. Privitera3, F. Bossa4, A. Lauria5, L. Grossi6, M. B. Principi7, N. Della Valle8, M. A. Veneziano9, D. Crocchiolo9

1University of Palermo, Gastroenterology Section, DiBiMis, Palermo, Italy, 2Università di Messina, Dipartimento di Medicina Interna e Terapia Medica, Messina, Italy, 3Azienda Ospedaliera per l’Emergenza, Ospedale Cannizzaro, Catania, Gastroenterologia, Catania, Italy, 4Casa Sollievo della Sofferenza, Gastroenterologia, S. Giovanni Rotondo, Foggia, Italy, 5A. O. Bianchi-Melacrino-Morelli, Reggio Calabria, Gastroenterologia e Endoscopia Digestiva, Reggio Calabria, Italy, 6Ospedale Spirito Santo, Pescara, Fisiopatologia Digestiva, Pescara, Italy, 7Policlinico, Department of Gastroenterology, Bari, Italy, 8Ospedale di Foggia, Gastroenterologia, Foggia, Italy, 9MSD Italy, Rome, Italy

P321: Mucosal healing in a cohort of inflammatory bowel diseases paediatric patients in clinical remissionECCO '16 Amsterdam
Year: 2016
Authors:

F. P. Giugliano1, C. Strisciuglio*2, M. Martinelli1, M. Andreozzi1, S. Cenni1, A. Staiano1, E. Miele1

1University Federico II, Department of Translational Medical Science, Section of Paediatrics, Naples, Italy, 2Second University of Naples, Department of Woman, Child and General and Specialised Surgery, Naples, Italy

P322: Complications to parenteral therapy in patients with intestinal failure because of inflammatory bowel disease: A retrospective cohort studyECCO '16 Amsterdam
Year: 2016
Authors:

R. Lorentsen, L. K. Munck, S. Wildt*

Køge University Hospital, and Faculty of Health Sciences, University of Copenhagen, Section of Gastroenterology, Medical Department, Køge, Denmark

P323: Prevalence of vitamin D deficiency in patients with inflammatory bowel diseaseECCO '16 Amsterdam
Year: 2016
Authors:

N. Toke*, P. Kakkadasam Ramaswamy, B. Sebastian, S. Mathai, C. Panackel

Medical Trust Hospital, Department of Gastroenterology, Ernakulam, India

P324: Comparative short and long-term efficacy of infliximab and adalimumab in patients with ulcerative colitis refractory to corticosteroids: a retrospective studyECCO '16 Amsterdam
Year: 2016
Authors:

N. Yoshimura*, M. Sako, M. Takazoe

Tokyo Yamate Medical Centre, Department of Internal Medicine, Tokyo, Japan